Romulus K. Brazzell - 27 Jun 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Head of Research and Development and Chief Medical Officer
Signature
/s/ Mary Reumuth, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
27 Jun 2022
Net transactions value
-$1,163
Form type
4
Filing time
29 Jun 2022, 20:11:12 UTC
Previous filing
05 Jan 2022
Next filing
28 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale $1,163 -3,144 -1.1% $0.3700 285,201 27 Jun 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.
F2 Includes 58,834 unvested RSUs.

Remarks:

Head of Research and Development and Chief Medical Officer